Interleukin-6 gene-174 G/C promoter polymorphism is not associated with multiple myeloma susceptibility: evidence from meta-analysis

摘要

Multiple myeloma [1,2,3,4] (MM) isa group ofmalignant plasmacellclonal diseases, with thecancercells thereof being derived fromthe plasma cells,and plasmacells [5] being thecells inwhichBlymphocytes [6] growto the ultimatefunctionalstage. The primary feature ofMMisabnormal proliferation of bone marrowplasmacells [7] with excessive production ofmonoclonalimmunoglobulin [8] or lightchain (Mprotein), [9,10] resulting in terminal organ damage. Theevolution ofMMis heterogeneous,and thesurvivaltime of patients with invasive manifestations isestimated to beless than 1 year. [11,12] Previous data highlighted that theincidence ofMMaccounts forabout 1%ofallsystemmalignant tumors, [13,14] often occurring inmiddle-aged and elderly patients, with theclinicalmanifestations thereof being complex and diverse, potentially causing anemia, infection, bleeding, bone pain,and even fracture. Alongwith theaforementioned issues, MMcould even lead to rareclinicalsymptoms, such as signs of nerveroot irritation. [15] As reported by existing research, theincidence ofmultiple myeloma has progressively increased worldwide over the past fewdecades, [16–18] substantially affecting the quality oflife of peopleand increasing the medicaland health burden ofsociety.